Edition:
United States

Immune Pharmaceuticals Inc (IMNP.OQ)

IMNP.OQ on NASDAQ Stock Exchange Capital Market

0.72USD
11:06am EST
Change (% chg)

$0.01 (+1.41%)
Prev Close
$0.71
Open
$0.72
Day's High
$0.72
Day's Low
$0.72
Volume
54,204
Avg. Vol
157,575
52-wk High
$5.02
52-wk Low
$0.70

Latest Key Developments (Source: Significant Developments)

Immune Pharmaceuticals reports Q3 results
Wednesday, 15 Nov 2017 08:34am EST 

Nov 15 (Reuters) - Immune Pharmaceuticals Inc :Immune Pharmaceuticals announces third quarter 2017 financial results and provides a corporate update.Immune Pharmaceuticals Inc - ‍Company recorded no revenue for three-month periods ended September 30, 2017 and 2016​.  Full Article

Immune Pharmac prices $18 mln public offering
Thursday, 19 Oct 2017 09:00am EDT 

Oct 19 (Reuters) - Immune Pharmaceuticals Inc :Immune Pharmaceuticals Inc announces pricing of $18,000,000 public offering of convertible preferred stock and warrants.Immune Pharmaceuticals Inc - ‍offering will be comprised of units, priced at a public offering price of $1,000 per unit​.  Full Article

Immune Pharmaceuticals announces positive results from ongoing phase 2 trial of bertilimumab
Wednesday, 27 Sep 2017 08:00am EDT 

Sept 27 (Reuters) - Immune Pharmaceuticals Inc :Immune Pharmaceuticals announces positive results from ongoing phase 2 trial of bertilimumab in bullous pemphigoid.Immune Pharmaceuticals Inc - ‍Results from three new subjects confirm and extend previous findings​.Immune Pharmaceuticals Inc says ‍bertilimumab was well tolerated in all six subjects and no serious adverse events were reported​.Immune Pharmaceuticals Inc - ‍Results from six subjects​ had no serious adverse events.Immune Pharmaceuticals Inc - ‍Will continue to enroll subjects into the phase 2 open label BP trial, which has target enrollment of 12 to 15 patients​.  Full Article

Immune Pharmaceuticals appoints Daniel Teper as CEO for Cytovia
Monday, 28 Aug 2017 08:00am EDT 

Aug 28 (Reuters) - Immune Pharmaceuticals ::Immune Pharmaceuticals provides research and development and business update and summary of recent financial highlights..Daniel Teper was named Chief Executive Officer of Cytovia..Rama Rao, a former Novartis executive, was appointed as Cytovia's interim CFO and COO..  Full Article

Immune Pharmaceuticals provides update on plan to spin-off Cytovia
Wednesday, 19 Jul 2017 09:32am EDT 

July 19 (Reuters) - Immune Pharmaceuticals Inc :Immune Pharmaceuticals provides update on plan to implement a spin-off of Cytovia into a separate publicly traded oncology company.Immune Pharmaceuticals Inc - Immune shareholders to receive additional pro rata shares in Cytovia​.Immune Pharmaceuticals Inc - new Cytovia, will focus on development and commercialization of novel immuno-oncology and hematology therapeutics.Immune Pharmaceuticals Inc - ‍it is contemplated that a pro rata distribution of shares in Cytovia would be issued to Immune shareholders as a dividend​.Immune Pharmaceuticals Inc - spin-off expected to create 2 independent publicly-traded cos with distinct strategic plans, leadership.Immune Pharmaceuticals Inc - initial core asset of Cytovia will be Ceplene.Immune Pharmaceuticals - ‍spin-off intended to take form of tax-free distribution to co's shareholders of common stock of a new publicly-traded Cytovia​.Immune Pharmaceuticals Inc - ‍immune will continue to be listed on Nasdaq under its existing symbol, "imnp."​.Immune Pharmaceuticals Inc - proposed Cytovia spin-off transaction will not require approval of Immune's shareholders.Immune Pharmaceuticals - Cytovia's strategic plan includes commercializing ceplene in select territories, consider potential acquisitions.Immune Pharmaceuticals Inc - transaction will allow Immune to become a pure play immuno-inflammation, clinical stage development company.  Full Article

Immune Pharma announces filing of patent protecting use of ceplene
Thursday, 13 Jul 2017 07:30am EDT 

July 13 (Reuters) - Immune Pharmaceuticals Inc ::Immune Pharmaceuticals announces filing of a patent protecting use of ceplene (histamine dihydrochloride) in hematologic cancers.Immune Pharmaceuticals Inc - ‍patent aims to protect use of ceplene in forms of cancer where malignant cells may harbor a mutated oncogene, NPM1​.  Full Article

Cytovia Inc enters agreement with Pint Pharma for licensing of Ceplene in Latin America
Tuesday, 11 Jul 2017 01:45pm EDT 

July 11 (Reuters) - Cytovia Inc : :Cytovia Inc, Immune Pharmaceuticals’ oncology subsidiary, enters into a definitive agreement with Pint Pharma for the licensing and commercialization of Ceplene® in Latin America.Cytovia Inc - Pint GMBH will separately enter into an investment agreement, which will lead to an investment of $4 million into Cytovia.Cytovia Inc - ‍"Intend to immediately initiate regulatory registration of Ceplene in Latam markets based on European approval​".Cytovia - Massimo Radaelli, executive chairman of Pint, will also join board of co upon completion of investment, effective spin off of co from Immune.  Full Article

Immune Pharmaceuticals' oncology unit announces additional clinical trial results on the efficacy of Ceplene in combination with low-dose IL-2 in patients with acute myeloid leukemia
Wednesday, 5 Jul 2017 08:30am EDT 

July 5 (Reuters) - Immune Pharmaceuticals Inc :Immune Pharmaceuticals' oncology subsidiary, Cytovia, announces additional clinical trial results on the efficacy of Ceplene® in combination with low-dose IL-2 in patients with acute myeloid leukemia, recently published in leukemia, a leading Hematology Journal.Immune Pharmaceuticals - ‍investigators said about 60% of AML patients who received treatment with Ceplene/IL-2 harbored NK cells potentially reactive with leukemic cells​.  Full Article

Immune Pharmaceuticals files for offering of upto 1.4 mln shares
Friday, 30 Jun 2017 04:33pm EDT 

June 30 (Reuters) - Immune Pharmaceuticals Inc ::Immune Pharmaceuticals Inc files for offering of upto 1.4 million shares of common stock by the selling stockholders - SEC filing.  Full Article

Immune Pharmaceuticals' Oncology subsidiary, Cytovia Inc. Provides update to proposed pint pharma transaction
Thursday, 29 Jun 2017 08:30am EDT 

June 29 (Reuters) - Immune Pharmaceuticals Inc :Immune pharmaceuticals' oncology subsidiary, cytovia inc. Provides update to proposed pint pharma transaction: substantial agreement reached on material terms of the licensing and commercialization of ceplene® in latin america.Immune pharmaceuticals inc - substantial agreement reached on material terms of licensing and commercialization of ceplene® in latin america.Immune pharmaceuticals inc - parties currently anticipate that they will execute a definitive licensing agreement within next five to seven business days.Immune pharmaceuticals inc - parties have agreed to enter into definitive agreement related to pint's commitment to invest $4 million into cytovia.Immune pharmaceuticals inc - "plan to pursue approval of ceplene in united states based on previously announced global overall survival study, remain".Immune pharmaceuticals inc - massimo radaelli, executive chairman of pint will join board of directors of cytovia following completion of investment.Immune pharmaceuticals - "plan is to commercialize ceplene in combination with low dose il-2 in all markets that accept european registration dossier as a basis for approval".  Full Article

BRIEF-Immune Pharmaceuticals reports Q3 results

* Immune Pharmaceuticals announces third quarter 2017 financial results and provides a corporate update